IL17A and atopic eczema: Pertinent examples include tumour necrosis factor inhibitor therapy triggering multiple sclerosis,1 interleukin 17 (IL-17) therapy for psoriasis linked to inflammatory bowel disease2 and more recently IL-4/13 blockade used for atopic dermatitis being associated with de novo psoriasis and arthritis.3 4